Traumatic Hematuria in Patients with Polycystic Kidney Disease

Klein, Andrew J. P.; Kozar, Rosemary A.; Kaplan, Lewis J.
May 1999
American Surgeon;May1999, Vol. 65 Issue 5, p464
Academic Journal
Presents a case report that discussed the management of traumatic hematuria in patient with autosomal dominant polycystic kidney disease (PKD). Clinical manifestation of the patient; Pathophysiology of the disease; Treatment modalities for the management of PKD.


Related Articles

  • Treatment of Persistent Gross Hematuria with Tranexamic Acid in Autosomal Dominant Polycystic Kidney Disease. Yao, Qing; Wu, Ming; Zhou, Jie; Zhou, Meiyang; Chen, Dongping; Fu, Lili; Bian, Rongrong; Xing, Xiaohong; Sun, Lijun; Hu, Xiaohong; Li, Lin; Dai, Bing; Wüthrich, Rudolf P.; Ma, Yiyi; Mei, Chang-Lin // Kidney & Blood Pressure Research;May2017, Vol. 42 Issue 1, p156 

    Background/Aims: In this retrospective study we aimed to compare the effect of tranexamic acid (TXA) vs etamsylate, two hemostatic agents, on hematuria duration in autosomal dominant polycystic kidney disease (ADPKD) patients with persistent gross hematuria. Methods: This is a retrospective...

  • Citrate therapy for polycystic kidney disease in rats. Tanner, George A.; Tanner, Judith A. // Kidney International;Nov2000, Vol. 58 Issue 5, p1859 

    Focuses on the effectiveness of citrate therapy for polycystic kidney disease (PKD) in rats. Characteristics of polycystic kidney disease; Influence of increased ammonia levels on damage in cystic kidneys; Effects of solution of potassium citrate plus citric acid consumption on function in...

  • Nephrologists Agree That There is a High Unmet Need for an Effective Treatment to Slow Renal Disease Progression in Polycystic Kidney Disease, According to a Recent BioTrends Report.  // Biomedical Market Newsletter;2/28/2012, Vol. 21, p1 

    The article reports on the biotrends observed in a survey which involved the nephrologists of the U.S. According to the physicians, new therapies are required for targeting the polycystic kidney disease (PKD) as no effective treatments are available for the treatment of this genetic disorder....

  • Aquaretic Treatment in Polycystic Kidney Disease. W�thrich, Rudolf P.; Mei, Changlin // New England Journal of Medicine;12/20/2012, Vol. 367 Issue 25, p2440 

    A reprint of the article "Aquaretic Treatment in Polycystic Kidney Disease," by Rudolf P. W�thrich that was previously published at NEJM.org on November 2, 2012 is presented. The article discusses the effectiveness of several drug candidates in slowing the progression of autosomal dominant...

  • Polycystic Kidney Disease in a Patient Using Lithium Chronically. ATAGÜN, Murat İlhan; ORAL, Esad Timuçin; SEVİNÇ, Can // Turk Psikiyatri Dergisi;Fall2013, Vol. 24 Issue 3, p1 

    Lithium remains to be the gold standard in the treatment of mood disorders. This study presents a case treated with lithium for an extended period with a good response. Following an increase in creatinine levels, further investigation of renal dysfunction revealed polycystic kidney disease....

  • Safety and Efficacy of Minimally Invasive Percutaneous Nephrolithotomy in Patients with Autosomal Dominant Polycystic Kidney Disease. Lei, Ming; Zhu, Wei; Wan, Shaw P.; Liu, Yongda; Zeng, Guohua; Yuan, Jian // Journal of Endourology;Jan2014, Vol. 28 Issue 1, p17 

    Purpose: To review our experience of using minimally invasive percutaneous nephrolithotomy (MPCNL) in patients with autosomal dominant polycystic kidney disease (ADPKD). Patients and Methods: We retrospectively reviewed 23 renal units in 23 patients with ADPKD who underwent MPCNL in our center...

  • The POWER of a PROTEIN. VANDAVEER, PAIGE // Vanguard (Oklahoma State University);Feb2013, p6 

    The article discusses a research study on the treatment for the genetic life-threatening Polycystic Kidney Disease (PKD) at the Oklahoma State University (OSU) Center for Veterinary Health Science. Research leader Dr. Myron Hinsdale says that animal models are important in studying how cells are...

  • Secreted frizzled-related protein 4 predicts progression of autosomal dominant polycystic kidney disease. Zschiedrich, Stefan; Budde, Klemens; Nürnberger, Jens; Wanner, Christoph; Sommerer, Claudia; Kunzendorf, Ulrich; Banas, Bernhard; Hoerl, Walter H.; Obermüller, Nicholas; Arns, Wolfgang; Pavenstädt, Hermann; Gaedeke, Jens; Lindner, Tom H.; Faerber, Lothar; Wimmer, Peter; Stork, Roland; Eckardt, Kai-Uwe; Walz, Gerd // Nephrology Dialysis Transplantation;Feb2016, Vol. 31 Issue 2, p284 

    Background. Autosomal dominant polycystic kidney disease (ADPKD) is a common autosomal dominant condition associated with renal cysts and development of renal failure. With the availability of potential therapies, one major obstacle remains the lack of readily available parameters that identify...

  • Autosomal Dominant Polycystic Kidney Disease: New Treatment Options and How to Test Their Efficacy. Wüthrich, Rudolf P.; Serra, Andreas L.; Kistler, Andreas D. // Kidney & Blood Pressure Research;2009, Vol. 32 Issue 5, p380 

    Autosomal dominant polycystic kidney disease (ADPKD) represents a slowly progressing cystic kidney disorder which evolves into end-stage renal disease in the majority of patients. Currently, there are no established treatments to retard the progression of the disease, but several promising...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics